Se connecter Inscription gratuite

Last updated: 4 May 2023 at 7:48am EST

Luisa Salter-Cid Net Worth




The estimated Net Worth of Luisa Salter Cid is at least $3.49 million dollars as of 23 March 2021. Ms. Cid owns over 5,491 units of Gossamer Bio stock worth over $183,398 and over the last 6 years she sold GOSS stock worth over $1,046,055. In addition, she makes $2,258,880 as Chief Scientific Officer at Gossamer Bio.

Ms. Cid GOSS stock SEC Form 4 insiders trading

Luisa has made over 2 trades of the Gossamer Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 5,491 units of GOSS stock worth $52,055 on 23 March 2021.

The largest trade she's ever made was selling 50,000 units of Gossamer Bio stock on 28 August 2019 worth over $994,000. On average, Luisa trades about 5,549 units every 57 days since 2019. As of 23 March 2021 she still owns at least 206,065 units of Gossamer Bio stock.

You can see the complete history of Ms. Cid stock trades at the bottom of the page.





Luisa Salter-Cid biography

Luisa Salter-Cid Ph.D. serves as Chief Scientific Officer of the Company. Prior to joining us, Dr. Salter-Cid worked at Bristol-Myers Squibb in increasing positions of responsibility from 2005 to August 2018, most recently as Vice President and Head of Immunology, small molecule Immuno-Oncology and Genomics Discovery where she focused on target validation and development of innovative biologic and small-molecule therapeutics to address significant unmet needs in autoimmune diseases and cancer. During her time at Bristol-Myers Squibb, Dr. Salter-Cid led teams that advanced more than 20 compounds into clinical development, and is an author on over 70 publications and patents. Previously, from 2002 to 2005, Dr. Salter-Cid was a Senior Project Leader at La Jolla Pharmaceuticals, Inc. Dr. Salter-Cid also held positions at Genset Corporation and Johnson & Johnson. She was a member of the Scientific Advisory Board of Enterome SA until July 2018. Dr. Salter-Cid holds a B.S. in Biology from University of Lisbon and a Ph.D. in Immunology from the University of Miami School of Medicine.

What is the salary of Luisa Cid?

As the Chief Scientific Officer of Gossamer Bio, the total compensation of Luisa Cid at Gossamer Bio is $2,258,880. There are 2 executives at Gossamer Bio getting paid more, with Jakob Dupont having the highest compensation of $3,530,450.



How old is Luisa Cid?

Luisa Cid is 61, she's been the Chief Scientific Officer of Gossamer Bio since 2018. There are 3 older and 12 younger executives at Gossamer Bio. The oldest executive at Gossamer Bio, Inc. is Thomas Daniel, 66, who is the Independent Director.

What's Luisa Cid's mailing address?

Luisa's mailing address filed with the SEC is 3013, Science Park Road, Torrey Pines, San Diego, San Diego County, California, 92121, United States.

Insiders trading at Gossamer Bio

Over the last 6 years, insiders at Gossamer Bio have traded over $10,765,709 worth of Gossamer Bio stock and bought 2,039,396 units worth $4,494,757 . The most active insiders traders include Kristina Burow, Faheem Hasnain et Fund V, L.P.Omega Fund V Gp.... On average, Gossamer Bio executives and independent directors trade stock every 33 days with the average trade being worth of $40,853. The most recent stock trade was executed by Richard Aranda on 24 June 2024, trading 1,908 units of GOSS stock currently worth $1,259.



What does Gossamer Bio do?

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.



What does Gossamer Bio's logo look like?

Gossamer Bio, Inc. logo

Complete history of Ms. Cid stock trades at Jounce Therapeutics Inc et Gossamer Bio

Date
#
Société
 Initié
Trans.
Transaction
 Actions Prix par action Prix ​​total Actions après Source
23 Mar 2021 GOSS Gossamer Bio, Inc. Luisa Salter Cid
Chief Scientific Officer
 Vente 5,491 $9.48 $52,055
23 Mar 2021
206,065 ↗
28 Aug 2019 GOSS Gossamer Bio, Inc. Luisa Salter Cid
Chief Scientific Officer
 Vente 50,000 $19.88 $994,000
28 Aug 2019
124,056 ↗


Gossamer Bio executives and stock owners

Gossamer Bio executives and other stock owners filed with the SEC include: